Personensuche
Personensuche
Es wurde 1 Person gefunden.
Medizinische Fakultät, Klinik für Frauenheilkunde und Geburtshilfe
Funktionen
-
Privatdozent/in, Klinik für Frauenheilkunde und Geburtshilfe
Aktuelle Veranstaltungen
Keine aktuellen Veranstaltungen.
Vergangene Veranstaltungen (max. 10)
Keine vergangenen Veranstaltungen.
Die folgenden Publikationen sind in der Online-Universitätsbibliographie der Universität Duisburg-Essen verzeichnet. Weitere Informationen finden Sie gegebenenfalls auch auf den persönlichen Webseiten der Person.
-
Efficacy of Lapatinib in Patients with HER2-Negative Metastatic Breast Cancer and HER2-Positive Circulating Tumor Cells-The DETECT III Clinical TrialIn: Clinical Chemistry Jg. 70 (2024) Nr. 1, S. 307 - 318Online Volltext: dx.doi.org/
-
Fibroblast Growth Factor Receptors and Ligands in Context of Bevacizumab Response in Ovarian Carcinoma : An Exploratory Analysis of AGO-OVAR11/ICON-7In: Laboratory Investigation Jg. 104 (2024) Nr. 4, 100321Online Volltext: dx.doi.org/
-
Breastfeeding Behavior Within the Covid-19 Related Obstetric and Neonatal Outcome Study (CRONOS)In: Journal of Human Lactation Jg. 39 (2023) Nr. 4, S. 625 - 635Online Volltext: dx.doi.org/
-
Depression and anxiety in women with malignant ovarian germ cell (MOGCT) and sex cord stromal tumors (SCST) : An analysis of the AGO-CORSETT databaseIn: Archives of Gynecology and Obstetrics Jg. 307 (2023) Nr. 4, S. 1155 - 1162Online Volltext: dx.doi.org/ (Open Access)
-
Establishment and Molecular Characterization of an In Vitro Model for PARPi-Resistant Ovarian CancerIn: Cancers Jg. 15 (2023) Nr. 15, 3774Online Volltext: dx.doi.org/ (Open Access)
-
Psychische Belastung und deren Einflussfaktoren bei Überlebenden von malignen ovariellen Keimzell- oder Keimstrangstromatumoren : Eine Analyse der AGO-CORSETT-DatenbankIn: Die Onkologie Jg. 29 (2023) Nr. 5, S. 447 - 454Online Volltext: dx.doi.org/ (Open Access)
-
Treatment strategies in patients with gynecological sarcoma : Results of the prospective intergroup real-world registry for gynecological sarcoma in Germany (REGSA-NOGGO RU1)In: International Journal of Gynecological Cancer Jg. 33 (2023) Nr. 2, S. 223 - 230Online Volltext: dx.doi.org/
-
Bevacizumab May Differentially Improve Prognosis of Advanced Ovarian Cancer Patients with Low Expression of VEGF-A₁₆₅b, an Antiangiogenic VEGF-A Splice VariantIn: Clinical Cancer Research Jg. 28 (2022) Nr. 21, S. 4660 - 4668Online Volltext: dx.doi.org/
-
FNTB Promoter Polymorphisms Are Independent Predictors of Survival in Patients with Triple Negative Breast CancerIn: Cancers Jg. 14 (2022) Nr. 3, 468Online Volltext: dx.doi.org/ (Open Access)
-
Total mesometrial resection (TMMR) for cervical cancer FIGO IB–IIA : First results from the multicentric TMMR register studyIn: Journal of Gynecologic Oncology Jg. 33 (2022) Nr. 1, e9Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Diminished PLK2 Induces Cardiac Fibrosis and Promotes Atrial FibrillationIn: Circulation Research Jg. 129 (2021) Nr. 8, S. 804 - 820Online Volltext: dx.doi.org/ (Open Access)
-
Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study programIn: ESMO Open Jg. 6 (2021) Nr. 6, 100299Online Volltext: dx.doi.org/ (Open Access)
-
The effect of fertility-sparing surgery on sexuality and global quality of life in women with malignant ovarian germ cell and sex cord stromal tumors : An analysis of the CORSETT database of the AGO study groupIn: Archives of Gynecology and Obstetrics Jg. 304 (2021) Nr. 6, S. 1541 - 1549Online Volltext: dx.doi.org/ (Open Access)
-
Diphenhydramine increases the therapeutic window for platinum drugs by simultaneously sensitizing tumor cells and protecting normal cellsIn: Molecular Oncology Jg. 14 (2020) Nr. 4, S. 686 - 703Online Volltext: dx.doi.org/ (Open Access)
-
Prognostic role of thrombocytosis in recurrent ovarian cancer : a pooled analysis of the AGO Study GroupIn: Archives of Gynecology and Obstetrics Jg. 301 (2020) Nr. 5, S. 1267 - 1274Online Volltext: dx.doi.org/
-
The effect of the triazene compound CT913 on ovarian cancer cells in vitro and its synergistic interaction with the PARP-inhibitor olaparibIn: Gynecologic Oncology Jg. 159 (2020) Nr. 3, S. 850 - 859Online Volltext: dx.doi.org/
-
Association of caspase 8 polymorphisms -652 6N InsDel and Asp302His with progression-free survival and tumor infiltrating lymphocytes in early breast cancerIn: Scientific Reports Jg. 9 (2019) Nr. 1, S. 12594Online Volltext: dx.doi.org/ (Open Access)
-
Extracellular vesicle-associated miRNAs in ovarian cancer - design of an integrated NGS-based workflow for the identification of blood-based biomarkers for platinum-resistanceIn: Clinical Chemistry and Laboratory Medicine Jg. 57 (2019) Nr. 7, S. 1053 - 1062Online Volltext: dx.doi.org/
-
Lymph node ratio in inguinal lymphadenectomy for squamous cell vulvar cancer : results from the AGO-CaRE-1 studyIn: Gynecologic Oncology Jg. 153 (2019) Nr. 2, S. 286 - 291Online Volltext: dx.doi.org/
-
Prognostic value of RANKL/OPG serum levels and disseminated tumor cells in nonmetastatic breast cancerIn: Clinical Cancer Research Jg. 25 (2019) Nr. 4, S. 1369 - 1378Online Volltext: dx.doi.org/ (Open Access)
-
What is the evidence for lymphadenectomy in presumed early ovarian cancer?In: Archives of Gynecology and Obstetrics Jg. 299 (2019) Nr. 1, S. 1 - 5Online Volltext: dx.doi.org/
-
Abstract OT1-03-05: The DETECT V-Study : Comparison of dual HER2-targeted therapy with trastuzumab plus pertuzumab in combination with chemo- or endocrine therapy in addition with CDK4/6 inhibition in patients with HER2-positive and hormone-receptor positive metastatic breast cancerIn: Cancer Research Jg. 78 (2018) Nr. 4, Supplement,Online Volltext: dx.doi.org/
-
DETECT III und IV - Individualized CTC-based therapy of metastatic breast cancerIn: Oncology Research and Treatment Jg. 41 (2018) Nr. Suppl. 1, S. 32
-
Fertility Preservation for Patients with Malignant Disease. : Guideline of the DGGG, DGU and DGRM (S2k-Level, AWMF Registry No. 015/082, November 2017) - Recommendations and Statements for Girls and WomenIn: Geburtshilfe und Frauenheilkunde Jg. 78 (2018) Nr. 6, S. 567 - 584Online Volltext: dx.doi.org/ (Open Access)
-
Human chorionic gonadotropin induces decidualization of ectopic human endometrium more effectively than forskolin in an in-vivo endometriosis modelIn: Experimental Biology and Medicine Jg. 243 (2018) Nr. 11, S. 953 - 962Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
The DETECT V-Study - Comparison of dual HER2-targeted therapy with Trastuzumab plus Pertuzumab in combination with Chemo- or Endocrine Therapy in Addition with CDK4/6 Inhibition in Patients with HER2-positive and Hormone-receptor positive Metastatic BreasIn: Oncology Research and Treatment Jg. 41 (2018) Nr. Suppl. 1, S. 33 - 33
-
Analysis of everolimus starting dose as prognostic marker in HR plus mBC patients treated with everolimus (EVE) plus exemestane (EXE) : Results of the 3rd interim analysis of the non-interventional trial BRAWOIn: Journal of Clinical Oncology (JCO) Jg. 35 (2017) Nr. Suppl. 15, S. 1061Online Volltext: dx.doi.org/
-
DETECT III and IV – Individualized CTC-based therapy of metastatic breast cancerIn: Cancer Research Jg. 77 (2017) Nr. 4, S. OT3 - 04Online Volltext: dx.doi.org/
-
EMT-like circulating tumor cells in ovarian cancer patients are enriched by platinum-based chemotherapyIn: OncoTarget Jg. 8 (2017) Nr. 30, S. 48820 - 48831Online Volltext: dx.doi.org/ (Open Access)
-
ERCC1-expressing circulating tumor cells as a potential diagnostic tool for monitoring response to platinum-based chemotherapy and for predicting post-therapeutic outcome of ovarian cancerIn: OncoTarget Jg. 8 (2017) Nr. 15, S. 24303 - 24313Online Volltext: dx.doi.org/ (Open Access)
-
Median progression free survival (PFS) for patients treated with everolimus (EVE) plus exemestane (EXE) for HR plus mBC in routine clinical practice : Results of the 3rd interim analysis of the non-interventional trial BRAWOIn: Journal of Clinical Oncology (JCO) Jg. 35 (2017) Nr. Suppl. 15, S. e12547Online Volltext: dx.doi.org/
-
Outcome After Sentinel Lymph Node Dissection in Vulvar Cancer : A Subgroup Analysis of the AGO-CaRE-1 StudyIn: Annals of Surgical Oncology Jg. 24 (2017) Nr. 5, S. 1314 - 1321Online Volltext: dx.doi.org/
-
Prognostic relevance of caspase 8 polymorphisms for breast cancerIn: Cancer Research Jg. 77 (2017) Nr. 4, S. P4 - 12Online Volltext: dx.doi.org/
-
Serum levels of RANKL are increased in primary breast cancer patients in the presence of disseminated tumor cells in the bone marrowIn: Cancer Research Jg. 77 (2017) Nr. 4,Online Volltext: dx.doi.org/
-
The DETECT V-study – Comparison of dual HER2-targeted therapy with trastuzumab plus pertuzumab in combination with chemo- or endocrine therapy in patients with HER2-positive and hormone-receptor positive metastatic breast cancerIn: Cancer Research Jg. 77 (2017) Nr. 4, S. OT1 - 02Online Volltext: dx.doi.org/
-
Analysis of disseminated tumor cells before and after platinum based chemotherapy in primary ovarian cancer : Do stem cell like cells predict prognosis?In: OncoTarget Jg. 7 (2016) Nr. 18, S. 26454 - 26464Online Volltext: dx.doi.org/ (Open Access)
-
Caspase-8 Polymorphisms As Independent Prongostic Factors For Survival In Breast Cancer PatientsIn: International Journal of Gynecological Cancer Jg. 26 (2016) Nr. Suppl. 2, S. 30Online Volltext: dx.doi.org/
-
Do disseminated tumor cells with stem cell character after therapy predict prognosis in primary ovarian cancerIn: Cancer Research Jg. 76 (2016) Nr. 14 Suppl., S. 2492Online Volltext: dx.doi.org/
-
Implementation of Enhanced Recovery After Surgery (ERAS) Pathways in Gynecologic Oncology : A NOGGO-AGO* survey of 144 Gynecological Departments in GermanyIn: Anticancer Research Jg. 36 (2016) Nr. 8, S. 4227 - 4232
-
Prognostic relevance of caspase 8 -652 6N InsDel and Asp302His polymorphisms for breast cancerIn: BMC Cancer Jg. 16 (2016) S. 618Online Volltext: dx.doi.org/ (Open Access)
-
Prognostische Relevanz von Caspase-8 Polymorphismen für das MammakarzinomIn: Geburtshilfe und Frauenheilkunde Jg. 76 (2016) Nr. 5, A 30Online Volltext: dx.doi.org/
-
ERCC1-positive circulating tumor cells in the blood of ovarian cancer patients as a predictive biomarker for platinum-restistanceIn: International Journal of Gynecological Cancer Jg. 25 (2015) Nr. 9 (Supplement 1), S. 464Online Volltext: dx.doi.org/
-
Quality of life and sexual function in patients with borderline tumors of the ovary : A substudy of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) study group ROBOT studyIn: Supportive Care in Cancer Jg. 23 (2015) Nr. 1, S. 117 - 123Online Volltext: dx.doi.org/
-
Single nucleotide polymorphisms of the EpCAM-coding gene TACSTD1 in patients with ovarian cancer and their potential translational aspectsIn: Archives of Gynecology and Obstetrics Jg. 292 (2015) Nr. 6, S. 1367 - 1372Online Volltext: dx.doi.org/
-
Surgical staging and prognosis in serous borderline ovarian tumours (BOT) : a subanalysis of the AGO ROBOT studyIn: British Journal of Cancer (BJC) Jg. 112 (2015) Nr. 4, S. 660 - 666Online Volltext: dx.doi.org/ (Open Access)
-
The FNTB promoter polymorphism rs11623866 as a potential predictive biomarker for lonafarnib treatment of ovarian cancer patientsIn: British Journal of Clinical Pharmacology (BJCP) Jg. 80 (2015) Nr. 5, S. 1139 - 1148Online Volltext: dx.doi.org/ (Open Access)
-
The value of serum CA125 in the diagnosis of borderline tumors of the ovary : A subanalysis of the prospective multicenter ROBOT studyIn: International Journal of Gynecological Cancer Jg. 25 (2015) Nr. 7, S. 1248 - 1252Online Volltext: dx.doi.org/ (Open Access)
-
Additional B-cell deficiency does not affect growth and angiogenesis of ectopic human endometrium in T-cell-deficient endometriosis mouse models during long-term cultureIn: Journal of Reproductive Immunology Jg. 106 (2014) Nr. 1, S. 50 - 57Online Volltext: dx.doi.org/
-
Age-dependent differences in borderline ovarian tumours (BOT) regarding clinical characteristics and outcome : Results from a sub-analysis of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) ROBOT studyIn: Annals of Oncology Jg. 25 (2014) Nr. 7, S. 1320 - 1327Online Volltext: dx.doi.org/
-
Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer : The AURELIA Open-Label Randomized Phase III TrialIn: Journal of Clinical Oncology (JCO) Jg. 32 (2014) Nr. 13, S. 1302 - 1308Online Volltext: dx.doi.org/
-
Circulating U2 Small Nuclear RNA Fragments as a Novel Diagnostic Tool for Patients with Epithelial Ovarian CancerIn: Clinical Chemistry Jg. 60 (2014) Nr. 1, S. 206 - 213Online Volltext: dx.doi.org/
-
ERCC1-Positive Circulating Tumor Cells in the Blood of Ovarian Cancer Patients as a Predictive Biomarker for Platinum ResistanceIn: Clinical Chemistry Jg. 60 (2014) Nr. 10, S. 1282 - 1289Online Volltext: dx.doi.org/
-
Efficacy and safety of AEZS-108 (INN: Zoptarelin Doxorubicin Acetate) an LHRH agonist linked to doxorubicin in women with platinum refractory or resistant ovarian cancer expressing LHRH receptors : A multicenter Phase II trial of the ago-study group (AGO GYN 5)In: Gynecologic Oncology Jg. 133 (2014) Nr. 3, S. 427 - 432Online Volltext: dx.doi.org/
-
Efficacy and safety of AEZS-108 (LHRH agonist linked to doxorubicin) in women with advanced or recurrent endometrial cancer expressing LHRH receptors : A multicenter phase 2 trial (AGO-GYN5)In: International Journal of Gynecological Cancer Jg. 24 (2014) Nr. 2, S. 260 - 265Online Volltext: dx.doi.org/ (Open Access)
-
Explorative investigation of vascular endothelial growth factor receptor expression in primary ovarian cancer and its clinical relevanceIn: Gynecologic Oncology Jg. 133 (2014) Nr. 3, S. 467 - 472Online Volltext: dx.doi.org/
-
Single nucleotide polymorphism of the EpCAM-coding gene TACSTD1 in patients with ovarian cancer and their potential implications in clinical practiceIn: Journal of Clinical Oncology (JCO) Jg. 32 (2014) Nr. 15 Suppl., S. e16515Online Volltext: dx.doi.org/
-
Synchronous ovarian and endometrial cancer-an international multicenter case-control studyIn: International Journal of Gynecological Cancer Jg. 24 (2014) Nr. 1, S. 54 - 60Online Volltext: dx.doi.org/
-
The FNTB-609G>C polymorphism as a possible predictive factor for efficacy of lonafarnib-treatment? : Exploratory analysis of a randomized phase II clinical trial in stage IIb-IV ovarian cancer, treated with first-line platinum-based chemotherapy with or without lonafarnibIn: Journal of Clinical Oncology (JCO) Jg. 32 (2014) Nr. 15 Suppl., S. e16534Online Volltext: dx.doi.org/
-
A phase II, randomized, double-blind study of zibotentan (ZD4054) in combination with carboplatin/paclitaxel versus placebo in combination with carboplatin/paclitaxel in patients with advanced ovarian cancer sensitive to platinum-based chemotherapy (AGO-OVAR 2.14)In: Gynecologic Oncology Jg. 130 (2013) Nr. 1, S. 31 - 37Online Volltext: dx.doi.org/
-
Abagovomab as maintenance therapy in patients with epithelial ovarian cancer : a phase III trial of the AGO OVAR, COGI, GINECO, and GEICO-the MIMOSA studyIn: Journal of Clinical Oncology (JCO) Jg. 31 (2013) Nr. 12, S. 1554 - 1561Online Volltext: dx.doi.org/
-
Borderline tumours of the ovary : a cohort study of the Arbeitsgmeinschaft Gynäkologische Onkologie (AGO) Study GroupIn: European Journal of Cancer (EJC) Jg. 49 (2013) Nr. 8, S. 1905 - 1914Online Volltext: dx.doi.org/
-
Clinical relevance of VEGF-receptor status in primary ovarian cancer : A pilot study for future biomarker analysesIn: Journal of Clinical Oncology (JCO) Jg. 31 (2013) Nr. 15, Suppl., S. 5556
-
Definition of compartment based radical surgery in uterine cancer-part I : therapeutic pelvic and periaortic lymphadenectomy by Michael höckel translated to robotic surgeryIn: ISRN Obstetrics and Gynecology (2013) S. 297921Online Volltext: dx.doi.org/
-
Definition of compartment-based radical surgery in uterine cancer : radical hysterectomy in cervical cancer as 'total mesometrial resection (TMMR)' by M Höckel translated to robotic surgery (rTMMR)In: World Journal of Surgical Oncology Jg. 11 (2013) S. 211Online Volltext: dx.doi.org/ (Open Access)
-
Definition of compartment-based radical surgery in uterine cancer : Modified radical hysterectomy in intermediate/high-risk endometrial cancer using peritoneal mesometrial resection (PMMR) by M Höckel translated to robotic surgeryIn: World Journal of Surgical Oncology Jg. 11 (2013) S. 198Online Volltext: dx.doi.org/ (Open Access)
-
Paraneoplastic hypercalcemia associated with juvenile granulosa cell tumorIn: Klinische Pädiatrie Jg. 225 (2013) Nr. 3, S. 170 - 171Online Volltext: dx.doi.org/
-
Pooled analysis of the prognostic relevance of disseminated tumor cells in the bone marrow of patients with ovarian cancerIn: International Journal of Gynecological Cancer Jg. 23 (2013) Nr. 5, S. 839 - 845Online Volltext: dx.doi.org/
-
Quality of life and sexual function in patients with borderline tumors of the ovary : A substudy of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) study group ROBOT studyIn: International Journal of Gynecological Cancer Jg. 23 (2013) Nr. Suppl. 8,
-
Serum mass spectrometry analysis in primary ovarian cancer (OC) treated with surgery and adjuvant chemotherapy (CT)In: Journal of Clinical Oncology (JCO) Jg. 31 (2013) Nr. Suppl. 15,
-
The persistence of ERCC1-positive circulating tumor cells predicts worse prognosis in patients with primary ovarian cancerIn: Cancer Research Jg. 73 (2013) Nr. Suppl. 8,Online Volltext: dx.doi.org/
-
Utility of mesothelin, L1CAM and afamin as biomarkers in primary ovarian cancerIn: Anticancer Research Jg. 33 (2013) Nr. 1, S. 329 - 336
-
A phase II trial (ago 2.11) in platinum-resistant ovarian cancer : a randomized multicenter trial with sunitinib (su11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor monotherapyIn: Annals of Oncology Jg. 23 (2012) Nr. 9, S. 2265 - 2271Online Volltext: dx.doi.org/ (Open Access)
-
Catumaxomab versus Catumaxomab plus prednisolone in patients with malignant ascites due to epithelial cancer : results from the casimas studyIn: Annals of Oncology Jg. 23 (2012) Nr. Suppl. 9, S. 539
-
Catumaxomab versus catumaxomab plus prednisolone in patients with malignant ascites due to epithelial cancer : results from the CASIMAS studyIn: Onkologie Jg. 35 (2012) Nr. Suppl. 6, S. 63 - 63
-
Decidualization in human ectopic endometrial lesions in vivo is induced by hCGIn: Human Reproduction Jg. 27 (2012) Nr. Suppl. 2, S. O - 203
-
Detection of disseminated tumor cells in bone marrow as an independent prognostic factor in primary ovarian cancer patientsIn: Journal of Clinical Oncology (JCO) Jg. 30 (2012) Nr. 15, Suppl.,
-
Deterioration in quality of life (QOL) in patients with malignant ascites : Results from a phase II/III study comparing paracentesis plus catumaxomab with paracentesis aloneIn: Annals of Oncology Jg. 23 (2012) Nr. 8, S. 1979 - 1985Online Volltext: dx.doi.org/ (Open Access)
-
Disease Progression in female Patients with borderline ovarian Tumors : Results of the multicentric AGO 'ROBOT' StudyIn: Geburtshilfe und Frauenheilkunde Jg. 72 (2012) Nr. 7, S. P15
-
Immunomonitoring Results of a Phase II/III Study of Malignant Ascites Patients Treated with the Trifunctional Antibody Catumaxomab (Anti-EpCAM × Anti-CD3)In: Cancer Research Jg. 72 (2012) Nr. 1, S. 24 - 32Online Volltext: dx.doi.org/
-
LOH at 6q and 10q in fractionated circulating DNA of ovarian cancer patients is predictive for tumor cell spread and overall survivalIn: BMC Cancer Jg. 12 (2012) S. 325Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Maintenance of quality of life (QoL) and general health state in patients with malignant ascites during treatment with the trifunctional antibody catumaxomab : results from the phase III b CASIMAS trialIn: Onkologie Jg. 35 (2012) Nr. Suppl. 6, S. 62 - 63
-
Maintenance of quality of life in patients with malignant ascites during treatment with the trifunctional antibody catumaxomab : results from the phase III B casimas trialIn: Annals of Oncology Jg. 23 (2012) Nr. Suppl. 9, S. 514
-
MicroRNA and the pathogenesis of ovarian cancer – a new horizon for molecular diagnostics and treatment?In: Clinical Chemistry and Laboratory Medicine Jg. 50 (2012) Nr. 4, S. 601 - 615Online Volltext: dx.doi.org/
-
Morbidity of inguinofemoral lymphadenectomy in vulval cancerIn: The Scientific World Journal (2012) S. 341253Online Volltext: dx.doi.org/
-
Open-label feasibility study of pazopanib, carboplatin, and paclitaxel in women with newly diagnosed, untreated, gynaecologic tumours : A phase I/II trial of the AGO study groupIn: British Journal of Cancer (BJC) Jg. 106 (2012) Nr. 4, S. 629 - 632Online Volltext: dx.doi.org/ (Open Access)
-
Randomized phase II trial of carboplatin and paclitaxel with or without lonafarnib in first-line treatment of epithelial ovarian cancer stage IIB-IVIn: Gynecologic Oncology Jg. 126 (2012) Nr. 2, S. 236 - 240Online Volltext: dx.doi.org/
-
Schlafende Tumorzellen : Widerstandskämpfer der gynäkologischen TumorerkrankungenIn: Unikate: Berichte aus Forschung und Lehre (2012) Nr. 42: Translationale Krebsforschung: Auf dem Weg zu neuen Therapien, S. 80 - 89Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Treatment of elderly ovarian cancer patients in the context of controlled clinical trials : A joint analysis of the AGO Germany experienceIn: Onkologie Jg. 35 (2012) Nr. 3, S. 76 - 81Online Volltext: dx.doi.org/
-
EpCAM-autoantibody levels in the course of disease of ovarian cancer patientsIn: Medical Oncology Jg. 28 (2011) Nr. 2, S. 626 - 630Online Volltext: dx.doi.org/
-
Impact of platinum-based chemotherapy on circulating nucleic acid levels, protease activities in blood and disseminated tumor cells in bone marrow of ovarian cancer patientsIn: International Journal of Cancer Jg. 128 (2011) Nr. 11, S. 2572 - 2580Online Volltext: dx.doi.org/ (Open Access)
-
Intraperitoneal treatment with the trifunctional bispecific antibody Catumaxomab in patients with platinum-resistant epithelial ovarian cancer : A phase IIa study of the AGO Study GroupIn: Gynecologic Oncology Jg. 123 (2011) Nr. 1, S. 27 - 32Online Volltext: dx.doi.org/
-
Loss of heterozygosity proximal to the M6P/IGF2R locus is predictive for the presence of disseminated tumor cells in the bone marrow of ovarian cancer patients before and after chemotherapyIn: Genes, Chromosomes and Cancer Jg. 50 (2011) Nr. 8, S. 598 - 605Online Volltext: dx.doi.org/
-
Molecular Profiling and Prognostic Relevance of Circulating Tumor Cells in the Blood of Ovarian Cancer Patients at Primary Diagnosis and After Platinum-Based ChemotherapyIn: International Journal of Gynecological Cancer Jg. 21 (2011) Nr. 5, S. 822 - 830Online Volltext: dx.doi.org/
-
Pegylated liposomal doxorubicin and carboplatin in malignant mixed epithelial mesenchymal and mesenchymal gynecologic tumors: A phase II trial of the AGO study groupIn: Journal of Clinical Oncology (JCO) Jg. 29 (2011) Nr. 15_suppl, S. 5093Online Volltext: dx.doi.org/
-
Prolonged ascites symptom-free time in patients with malignant ascites after treatment with catumaxomabIn: Onkologie Jg. 34 (2011) Nr. Suppl. 6, S. 167 - 168
-
Prädiktoren psychischer Belastungen bei Brustkrebspatientinnen : Worauf sollten Ärzte und Pflegekräfte in der onkologischen Praxis achten?In: Geburtshilfe und Frauenheilkunde Jg. 71 (2011) Nr. 4, S. 285 - 291Online Volltext: dx.doi.org/
-
The prognostic impact of circulating proteasome concentrations in patients with epithelial ovarian cancerIn: Gynecologic Oncology Jg. 120 (2011) Nr. 2, S. 233 - 238Online Volltext: dx.doi.org/
-
Tumour exosomes inhibit binding of tumour-reactive antibodies to tumour cells and reduce ADCC.In: Cancer Immunology, Immunotherapy Jg. 60 (2011) Nr. 5, S. 639 - 648Online Volltext: dx.doi.org/
-
378 Phase II study of AEZS-108 (AN-152), a targeted cytotoxic LHRH analog, in patients with LHRH receptor positive endometrial cancer. Protocol AGO-GYN 5, AGO Study Group, GermanyIn: European Journal of Cancer / EJC Supplements Jg. 8 (2010) Nr. 7, S. 120Online Volltext: dx.doi.org/ (Open Access)
-
A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignanciesIn: Annals of Oncology Jg. 21 (2010) Nr. 2, S. 370 - 375Online Volltext: dx.doi.org/ (Open Access)
-
Addition of vandetanib to pegliposomal doxorubicin (PLD) in patients with recurrent ovarian cancer. A phase I randomised phase II trial of the AGO-OVAR. Results of the first safety analysisIn: Onkologie Jg. 33 Suppl. 2 (2010) S. 112 - 112
-
Combination therapy with pegliposomal doxorubicin and carboplatin in malignant mixed epithelial mesenchymal gynecologic tumors. A prospective multicenter phase-II trial of the AGO Study GroupIn: Onkologie Jg. 33 Suppl. 2 (2010) S. 107 - 108
-
Immunomonitoring results of a pivotal phase II/III study with the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) in patients with malignant ascitesIn: Onkologie Jg. 33 Suppl. 2 (2010) S. 158 - 158
-
Impact of disseminated tumor cells in bone marrow on outcome of patients with primary ovarian cancerIn: Journal of Clinical Oncology (JCO) Jg. 28 (2010) Nr. Suppl. 15, S. e15545Online Volltext: dx.doi.org/
-
Influence of residual tumor on outcome in ovarian cancer patients with FIGO stage IV diseaseIn: Annals of Surgical Oncology Jg. 17 (2010) Nr. 6, S. 1642 - 1648Online Volltext: dx.doi.org/
-
Pharmacokinetics, immunogenicity and bioactivity of the therapeutic antibody catumaxomab intraperitoneally administered to cancer patientsIn: British Journal of Clinical Pharmacology (BJCP) Jg. 69 (2010) Nr. 6, S. 617 - 625Online Volltext: dx.doi.org/
-
Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancerIn: Journal of Clinical Oncology (JCO) Jg. 28 (2010) Nr. 27, S. 4162 - 4169Online Volltext: dx.doi.org/
-
Prognostic role of platinum sensitivity in patients with brain metastases from ovarian cancer : Results of a German multicenter studyIn: Annals of Oncology Jg. 21 (2010) Nr. 11, S. 2201 - 2205Online Volltext: dx.doi.org/ (Open Access)
-
The CYP1A1 Ile462Val polymorphism and platinum resistance of epithelial ovarian neoplasmsIn: Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics Jg. 18 (2010) Nr. 7, S. 343 - 347Online Volltext: dx.doi.org/
-
The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer : Results of a prospective randomized phase II/III trialIn: International Journal of Cancer Jg. 127 (2010) Nr. 9, S. 2209 - 2221Online Volltext: dx.doi.org/ (Open Access)
-
Association of the AA genotype of the BCL2 (-938C>A) promoter polymorphism with better survival in ovarian cancerIn: The International Journal of Biological Markers (IJBM) Jg. 24 (2009) Nr. 4, S. 223 - 229Online Volltext: dx.doi.org/
-
The AA genotype of a L1C G842A polymorphism is associated with an increased risk for ovarian cancer.In: Anticancer Research Jg. 29 (2009) Nr. 8, S. 3449 - 3452
-
The haplotype of two FSHR polymorphisms in ovarian cancer : A potential role of ethnology in risk modificationIn: Gynecologic Oncology Jg. 112 (2009) Nr. 3, S. 486 - 489Online Volltext: dx.doi.org/
-
Influence of platinum-based chemotherapy on disseminated tumor cells in blood and bone marrow of patients with ovarian cancerIn: Gynecologic Oncology Jg. 107 (2007) Nr. 2, S. 331 - 338Online Volltext: dx.doi.org/
-
Corrigendum to “Borderline tumours of the ovary: A cohort study of the Arbeitsgemeinschaft Gynäkologische Onkologie AGO Study Group”In: European Journal of Cancer (EJC) Jg. 65 (2016) S. 192 - 193Online Volltext: dx.doi.org/
-
Diagnosis of first relapse and its impact on quality of life in patients with advanced ovarian cancer (AGO-OVAR 19/II)In: Journal of Clinical Oncology (JCO) Jg. 40 (2022) Nr. 16_Suppl., S. e17609Online Volltext: dx.doi.org/ (Open Access)
-
Immunohistochemical expression of the anti-angiogenic VEGF-A splice variant VEGF-A165b as predictive biomarker for bevacizumab treatment in advanced ovarian cancer patients
15. Jahrestagung der Mitteldeutschen Gesellschaft für Frauenheilkunde und Geburtshilfe e.V. (MGFG), 17.-18.06.2022, Halle an der Saale,In: Geburtshilfe und Frauenheilkunde Jg. 82 (2022) Nr. 6: Kongressabstracts zur 15. Jahrestagung der Mitteldeutschen Gesellschaft für Frauenheilkunde und Geburtshilfe e.V. (MGFG), S. E30 - E31Online Volltext: dx.doi.org/ -
Prospective, multicenter study on non-pharmacological, patient related predictive factors of chemotherapy induced nausea and vomiting (CINV) : A NOGGO-EMRISK trialIn: Journal of Clinical Oncology (JCO) Jg. 40 (2022) Nr. 16_Suppl., S. e24107Online Volltext: dx.doi.org/ (Open Access)
-
Image-based identification of single circulating tumor cells in ovarian cancer patients for genomic analysis
AACR Annual Meeting 2021, April 10-15, 2021 and May 17-21, 2021, Philadelphia, PA, USA,In: Cancer Research Jg. 81 (2021) Nr. Suppl. 13, 594Online Volltext: dx.doi.org/ -
Carboplatin/PLD/Bevacizumab als neue Standardtherapieoption beim Ovarialkarzinomspätrezidiv – aktuelle Ergebnisse der AGO OVAR 2.21 StudieIn: Geburtshilfe und Frauenheilkunde Jg. 80 (2020) Nr. 10, S. e91Online Volltext: dx.doi.org/
-
The effect of surgical techniques on sexuality and global quality of life (Qol) in women with ovarian germ cell (OGCT) and sex cord stromal tumours (SCST) : An analysis of the AGO-CORSETT databaseIn: Annals of Oncology Jg. 31 (2020) Nr. Suppl. 4, S. S643 - S644Online Volltext: dx.doi.org/ (Open Access)
-
Association of Caspase 8 polymorphisms with TILs and disease-free survival in primary breast cancer patientsIn: Journal of Clinical Oncology (JCO) Jg. 36 (2018) Nr. Suppl. 15, S. e24258Online Volltext: dx.doi.org/ (Open Access)
-
ERCC1-Expressinf Circulating Tumor Cells as a Potential Diagnostic Tool for Monitoring Platinum-Based Chemotherapy and for Predicting Outcome of Ovarian CancerIn: International Journal of Gynecological Cancer Jg. 27 (2017) Nr. Suppl. 4, S. ESGO7 - 0140Online Volltext: dx.doi.org/
-
Analysis of disseminated tumor cells before and after platinum-based chemotherapy in primary ovarian cancer : Do stem cell like cells predict prognosis?
Krebsmedizin heute: präventiv, personalisiert, präzise und partizipativ ; 32. Deutscher Krebskongress ; 24.-27. Februar 2016, Berlin,In: Oncology Research and Treatment Jg. 39 (2016) Nr. Suppl. 1, S. 22Online Volltext: dx.doi.org/ -
Circulating U2 small nuclear RNA fragments as a novel diagnostic tool for patients with epithelial ovarian cancer
Krebsmedizin heute: präventiv, personalisiert, präzise und partizipativ ; 32. Deutscher Krebskongress ; 24.-27. Februar 2016, Berlin,In: Oncology Research and Treatment Jg. 39 (2016) Nr. Suppl. 1, S. 95 - 96Online Volltext: dx.doi.org/ -
The DETECT Study Concept - Metastatic breast cancer and circulating tumor cellsIn: Oncology Research and Treatment Jg. 39 (2016) Nr. Suppl. 1: Krebsmedizin heute: präventiv, personalisiert, präzise und partizipativ 32. Deutscher Krebskongress (DKK), Berlin, Februar 2016: Abstracts, S. 46 - 47
-
The DETECT study program - Personalized treatment in metastatic breast cancer based on circulating tumor cells
Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium, December 8-12, 2015, San Antonio, TX, USA,In: Cancer Research Jg. 76 (2016) Nr. 4, Supplement, OT1-02-02Online Volltext: dx.doi.org/ -
The FNTB-609G > C polymorphism as a possible predictive factor for efficacy of lonafarnib-treatment? : Exploratory analysis of a randomized phase II clinical trial in stage IIb-IV ovarian cancer, treated with first-line platinum-based chemotherapy with or without lonafarnib
Deutsche Gesellschaft für Experimentelle und Klinische Pharmakologie und Toxikologie e.V., 81th Annual Meeting, March 10 - 12, 2015, Kiel, Germany,In: Naunyn-Schmiedeberg's Archives of Pharmacology Jg. 388 (2015) Nr. Suppl. 1, S. 52Online Volltext: dx.doi.org/ -
AGO Vulva CaRE-1 multicenter study - adjuvant radio(chemo)therapy in vulvar cancer
31. Deutscher Krebskongress iKON - intelligente Konzepte in der Onkologie, 19.-22. Februar 2014, Berlin,In: Oncology Research and Treatment Jg. 37 (2014) Nr. Suppl. 1, S. 70Online Volltext: dx.doi.org/ -
Influence of the postoperative residual tumor on the outcome of therapy with pazopanib in ovarian cancer (OC) : A subgroup analysis of an international intergroup trial (AGO-OVAR16)
31. Deutscher Krebskongress iKON - intelligente Konzepte in der Onkologie, 19.-22. Februar 2014, Berlin,In: Oncology Research and Treatment Jg. 37 (2014) Nr. Suppl. 1, S. 69Online Volltext: dx.doi.org/ -
Outcome parameters in node-negative vulvar cancer - subset analysis of the AGO CaRE-1 study
31. Deutscher Krebskongress iKON - intelligente Konzepte in der Onkologie, 19.-22. Februar 2014, Berlin,In: Oncology Research and Treatment Jg. 37 (2014) Nr. Suppl. 1, S. 72 - 73Online Volltext: dx.doi.org/ -
Prognostic impact of the time interval between primary and re-staging surgery in patients with borderline ovarian tumours (BOT) : An analysis of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group
31. Deutscher Krebskongress iKON - intelligente Konzepte in der Onkologie, 19.-22. Februar 2014, Berlin,In: Oncology Research and Treatment Jg. 37 (2014) Nr. Suppl. 1, S. 71 - 71Online Volltext: dx.doi.org/ -
Resection margin and locoregional control in vulvar cancer : A subset analysis of the AGO CARE-1 multicenter studyIn: Journal of Clinical Oncology (JCO) Jg. 32 (2014) Nr. 15, Suppl., S. 5608Online Volltext: dx.doi.org/
-
The detection of excision repair cross-complementing rodent repair deficiency, complementation group 1-positive circulating tumor cells in the blood of ovarian cancer patients as a predictive biomarker for platinum-resistance
31. Deutscher Krebskongress iKON - intelligente Konzepte in der Onkologie, 19.-22. Februar 2014, Berlin,In: Oncology Research and Treatment Jg. 37 (2014) Nr. Suppl. 1, S. 3Online Volltext: dx.doi.org/ -
Converting EORTC QOl-C30 Scores to Utility Values : Is it Plausible?In: Value in Health Jg. 15 (2012) Nr. 7, S. A478Online Volltext: dx.doi.org/ (Open Access)
-
MicroRNA-1246 as a novel candidate for a blood-based biomarker in ovarian cancer patientsIn: Cancer Research Jg. 72 (2012) Nr. 8, Suppl., S. 4132Online Volltext: dx.doi.org/
-
PCN117 Quality of Life in Patients With Malignant Ascites After Treatment With Catumaxomab : A Multicenter Phase II/III Study Comparing Paracentesis Plus Catumaxomab With Paracentesis AloneIn: Value in Health Jg. 15 (2012) Nr. 7, S. A430 - A431Online Volltext: dx.doi.org/ (Open Access)
-
Quality of life in patients with malignant ascites and after treatment with catumaxomab : results from a phase II/III study comparing paracentesis plus catumaxomab with paracentesis aloneIn: Geburtshilfe und Frauenheilkunde Jg. 72 (2012) Nr. 4, S. A12Online Volltext: dx.doi.org/
-
Are mesothelin and L1CAM useful biomarkers in primary ovarian cancer patients?In: Journal of Clinical Oncology (JCO) Jg. 29 (2011) Nr. 15, Suppl., S. e15559Online Volltext: dx.doi.org/
-
Primary tumor loss of heterozygosity proximal to M6P/IGF2R locus is predictive for the presence and persistence of disseminated tumor cells in the bone marrow of ovarian cancer patientsIn: Cancer Research Jg. 71 (2011) Nr. 8, Suppl., S. 2217Online Volltext: dx.doi.org/
-
Quality of Life in Patients With Malignant Ascites and Ascites Symptoms After Treatment With Catumaxomab : Results From a Multicenter Phase ll/lll Study Comparing Paracentesis Plus Catumaxomab With Paracentesis AloneIn: European Journal of Cancer (EJC) Jg. 47 (2011) Nr. Suppl. 1, S. S223Online Volltext: dx.doi.org/
-
Basic principles of dose intensity and high-dose chemotherapyIn: Chemotherapy for Gynecological Neoplasms: Current Therapy and Novel Approaches / Angioli, Roberto (Hrsg.) 2004, S. 57 - 65
-
Efficacy of the tyrosine kinase inhibitor lapatinib in the treatment of patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells : results from the randomized phase III DETECT III trial
San Antonio Breast Cancer Virtual Symposium ; December 8-11, 2020; San Antonio, Texas,In: Cancer Research Jg. 81 (2021) Nr. 4, Supplement, S. PD3 - 12Online Volltext: dx.doi.org/ -
Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program
San Antonio Breast Cancer Virtual Symposium ; December 8-11, 2020; San Antonio, Texas,In: Cancer Research Jg. 81 (2021) Nr. 4, Supplement, S. PS2 - 02Online Volltext: dx.doi.org/